U.S. News Debuts GLP-1 Telehealth Platform Rankings Amid Surging Demand — U.S. News & World Report, L.P.

Event summary

U.S. News & World Report released its first-ever rankings of GLP-1 telehealth platforms on August 12, 2026.
The ratings evaluated 20 platforms offering FDA-approved GLP-1 medications like Wegovy and Ozempic.
11 platforms received top ratings based on clinical support, pricing transparency, and insurance assistance.
Amazon One Medical was named best for insurance support, while Found led in clinical support.

The big picture

The rankings arrive as GLP-1 medications reshape the healthcare landscape, with 52% of experts in a U.S. News survey citing expanded use as the top health trend for 2026. The telehealth sector is rapidly evolving to meet surging demand, but consumers face challenges navigating complex fee structures and varying levels of medical oversight. U.S. News' entry into this space signals growing institutional interest in standardizing quality metrics across digital weight management platforms.

What we're watching

Market Consolidation: Whether the rankings will accelerate consolidation among telehealth providers as top performers gain market share.
Regulatory Scrutiny: The pace at which regulators may intervene in GLP-1 telehealth services amid rising demand and potential safety concerns.
Platform Differentiation: How specialized platforms like Found and Noom will maintain their competitive edge against integrated players like Amazon One Medical.